Skip to content

Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant Laparoscopic Inguinal or Umbilical Herniorrhaphy

A Phase II, Single-dose, Open-label Study to Investigate the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Laparoscopic Inguinal or Umbilical Herniorrhaphy

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01224145
Enrollment
10
Registered
2010-10-19
Start date
2011-03-22
Completion date
2011-06-20
Last updated
2020-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hernia, Postoperative Pain

Brief summary

This study will assess pain intensity for the first 72 hrs after aggravated movement (cough) following Laparoscopic Inguinal or Umbilical Herniorrhaphy.

Detailed description

Inguinal herniorrhaphy is a common surgery; approximately 2,800 per million people in the United States (US) undergo the procedure annually.Common surgical methods of herniorrhaphy include open and laparoscopic placement of synthetic mesh. Studies have shown that the use of synthetic mesh greatly reduces the risk of hernia recurrence regardless of the method used for its placement. Furthermore, utilizing the laparoscopic approach for umbilical hernia repair, specifically with the use of mesh, may also reduce the risk of infection. Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes from cow tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery. This open-label study will assess pain intensity after surgery in patients who receive the CollaRx Bupivacaine implant as well as determine the feasibility of the use of the laparoscope for sponge placement in laparoscopic hernia repair.

Interventions

DRUG5x5cm bupivacaine collagen sponges

Sponsors

Premier Research
CollaboratorOTHER
Innocoll
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

laparoscope for bupivacaine sponge (200 mg bupivacaine hydrochloride) placement in laparoscopic hernia repair.

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Man ≥18 years 2. Has a planned unilateral inguinal herniorrhaphy (laparoscopy, transabdominal preperitoneal \[TAPP\] approach or totally extraperitoneal \[TEP\] approach) or laparoscopic umbilical herniorrhaphy to be performed according to standard surgical technique under general anesthesia. 3. Willing to use opioid rescue analgesia.

Exclusion criteria

1. Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products. 2. Scheduled for bilateral inguinal herniorrhaphy. 3. Undergone a prior herniorrhaphy at the location scheduled for repair. 4. Undergone major surgery within 3 months of the scheduled herniorrhaphy.

Design outcomes

Primary

MeasureTime frameDescription
Total Use of Opioid Analgesia - Morphine Equivalence (mg)0 to 24 hours after surgeryDosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)25-48 hoursDosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
Total Use of Opioid Rescue Analgesia Morphine Equivalence (mg)0-48 hours)Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Countries

United States

Participant flow

Participants by arm

ArmCount
Drug: Bupivacaine Collagen Sponge
4, 5x5 bupivacaine collagen sponges 4, 5x5cm bupivacaine collagen sponges
10
Total10

Baseline characteristics

CharacteristicDrug: Bupivacaine Collagen Sponge
Age, Continuous48 years
STANDARD_DEVIATION 9.76
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Region of Enrollment
United States
10 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 10
other
Total, other adverse events
8 / 10
serious
Total, serious adverse events
1 / 10

Outcome results

Primary

Total Use of Opioid Analgesia - Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame: 0 to 24 hours after surgery

ArmMeasureValue (MEAN)Dispersion
Bupivacaine Collagen SpongeTotal Use of Opioid Analgesia - Morphine Equivalence (mg)19.3 Morphine Equivalence (mg)Standard Deviation 15.5
Primary

Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame: 25-48 hours

ArmMeasureValue (MEAN)Dispersion
Bupivacaine Collagen SpongeTotal Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)5.3 Morphine Equivalence (mg)Standard Deviation 7.3
Primary

Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame: 49-72 Hours

ArmMeasureValue (MEAN)Dispersion
Bupivacaine Collagen SpongeTotal Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)2.0 Morphine Equivalence (mg)Standard Deviation 3.3
Primary

Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame: 0-72 hours

ArmMeasureValue (MEAN)Dispersion
Bupivacaine Collagen SpongeTotal Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)26.6 Morphine Equivalence (mg)Standard Deviation 23.2
Primary

Total Use of Opioid Rescue Analgesia Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame: 0-48 hours)

ArmMeasureValue (MEAN)Dispersion
Bupivacaine Collagen SpongeTotal Use of Opioid Rescue Analgesia Morphine Equivalence (mg)24.6 Morphine Equivalence (mg)Standard Deviation 21.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026